glp-1 for ckd Design and discovery of a highly potent ultralong-acting and glucagon co-agonist attenuating renal fibrosis GLP-1 therapy CKD - Diabetes
Description
World Journal of Gastroenterology
Even modest doses can help fix the hormonal cascade driving metabolic dysfunction
Endocrinology (2013) 154(1):48
In this trial, the relative MACE risk reduction was 20% (HR, 0.80
Incretins are released after eating and augment the secretion of insulin released from pancreatic beta cells of the islets of Langerhans by a blood-glucose-dependent mechanism
the real goal of weight loss GLP-1 medications can absolutely be powerful tools
